

# A platform study to evaluate investigational therapies in chronic hepatitis B infection

<b>Submission date</b> 25/09/2022	<b>Recruitment status</b> Stopped	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 28/09/2022	<b>Overall study status</b> Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 27/03/2024	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

The purpose of this research study is to test different experimental study drug(s) in people with chronic hepatitis B virus (HBV) infection. The main goals of the research study are to study if the experimental drugs are safe, how the study drugs interact with the patient's body, do the study drugs cause any side effects, can the study drugs reduce levels of HBV particles in the body, and measure how much study drugs are found in the blood over time.

### Who can participate?

Adults with chronic HBV infection

### What does the study involve?

The research study duration for each sub-protocol will have a screening period that could be up to 8 weeks, an on-treatment period that will have a minimum of 8 weeks, and a follow-up period that will have a minimum of 24 weeks. The sub-protocols will include different groups (or cohorts) and each group may evaluate different doses, different dosing schedules, and different combinations of the study drugs. Assignment to a cohort within a sub-protocol will be done in order based on available open cohorts. Study procedures include but are not limited to routine blood and urine tests, HBV blood tests, and physical examinations.

### What are the possible benefits and risks of participating?

A possible benefit is that the study drugs may reduce viral particles in the participant's blood or help activate the immune system to fight HBV. Potential risks in participating are outlined in the participant's informed consent forms.

### Where is the study run from?

Vir Biotechnology Inc (USA)

### When is the study starting and how long is it expected to run for?

January 2022 to March 2027

### Who is funding the study?

Vir Biotechnology Inc (USA)

Who is the main contact?  
Briana (Project Manager) (New Zealand)  
Briana.Kawaihae@novotech-cro.com

## Contact information

### Type(s)

Principal investigator

### Contact name

Prof Edward Gane

### Contact details

Auckland City Hospital  
2 Park Road Grafton  
Auckland 1010  
Auckland  
New Zealand  
1010  
+64 21 581 015  
liverresearchunit@adhb.govt.nz

### Type(s)

Scientific

### Contact name

Ms Vir Biotechnology

### Contact details

499 Illinois St  
Suite 500  
San Francisco  
United States of America  
CA 94158  
+1 415-654-5281  
clinicaltrials@vir.bio

### Type(s)

Public

### Contact name

Mr Vir Biotechnology

### Contact details

499 Illinois St  
Suite 500  
San Francisco  
United States of America

CA 94158  
+1 415 654 5281  
clinicaltrials@vir.bio

## Additional identifiers

**Clinical Trials Information System (CTIS)**  
2022-002014-16

**Protocol serial number**  
VIR-MHB1-200

## Study information

### Scientific Title

A platform study evaluating the efficacy and safety of investigational therapies in participants with chronic hepatitis B infection (PREVAIL)

### Acronym

PREVAIL

### Study objectives

Phase Ib sub-protocols will be exploratory, and no formal hypothesis testing will be conducted. In phase II sub-protocols, the null hypothesis is that the response rate is the same as in NRTI-suppressed patients. It is assumed that  $\leq 2\%$  of NRTI-suppressed patients will achieve a response rate. The alternative hypothesis will be described in the sub-protocol.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Approved 02/09/2022, (Central) Health & Disability Ethics Committee (Ministry of Health, 133 Molesworth Street, PO Box 5013, Wellington, 6011, New Zealand; +64 (0)800 4 38442; hdecs@health.govt.nz), ref: 2022 FULL 12906.

### Primary study design

Interventional

### Study design

Multicentre parallel-assignment open-label Phase Ib/II platform study

### Study type(s)

Treatment

### Health condition(s) or problem(s) studied

Chronic hepatitis B infection

### Interventions

Sub-Protocol A (STRIVE): Participants will receive combination therapy with VIR-3434, VIR-2218, PEG-IFN $\alpha$ , and/or TD/TDF up to 48 weeks total

#### Assigned interventions:

Drug: VIR-3434

VIR-3434 given by subcutaneous injection

Drug: VIR-2218

VIR-2218 given by subcutaneous injection

Drug: TD/TDF

TD/TDF given orally

Drug: PEG-IFNa

PEG-IFNa given by subcutaneous injection

#### Sub-Protocol B (THRIVE):

Participants will receive combination therapy with VIR-3434, VIR-2218, and/or TD/TDF up to 44 weeks total

#### Assigned interventions:

Drug: VIR-3434

VIR-3434 given by subcutaneous injection

Drug: VIR-2218

VIR-2218 given by subcutaneous injection

Drug: TD/TDF

TD/TDF given orally

#### Intervention Type

Drug

#### Phase

Phase II

#### Drug/device/biological/vaccine name(s)

VIR-2218, VIR-3434, pegylated interferon alfa-2a (PEG-IFNa or Pegasys®), tenofovir disoproxil /tenofovir disoproxil fumarate (TD/TDF; Viread®)

#### Primary outcome(s)

1. Proportion of participants achieving sustained suppression of HBV DNA (< lower limit of quantification [LLOQ]) at 24 weeks after discontinuation of all treatment
2. Proportion of participants achieving sustained suppression of HBV DNA (< LLOQ) with HBsAg loss (< 0.05 IU/mL) at 24 weeks after discontinuation of all treatment
3. Proportion of participants with Hepatitis B surface antigen (HBsAg) loss (<0.05 IU/ml) at the end of treatment
4. Proportion of participants with HBsAg loss (<0.05 IU/ml) at 24 weeks post-end of treatment
5. Mean change in serum HBsAg from baseline across time points in the study

#### STRIVE:

6. Proportion of participants with HBsAg loss (< 0.05 IU/ml) at the end of treatment

#### THRIVE:

7. Proportion of participants with HBsAg loss (<0.05 IU/ml) at the end of treatment

All outcomes measured using drawn blood

#### Key secondary outcome(s)

1. Proportion of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) during the study
2. Proportion of participants with serum HBsAg  $\leq 10$  IU/ml at end of treatment
3. Proportion of participants with serum HBsAg  $\leq 10$  IU/ml at 24 weeks post-end of treatment
4. Serum HBsAg levels and change from baseline across time points in the study
5. Serum HBsAg level at nadir during the study
6. Time to achieve nadir of serum HBsAg during the study
7. Time to achieve serum HBsAg loss ( $< 0.05$  IU/ml)
8. Proportion of participants with HBsAg loss with anti-HBs seroconversion at end of treatment and at 24 weeks post-end of treatment

#### STRIVE:

9. Proportion of participants with HBsAg loss ( $< 0.05$  IU/mL) at 24 weeks post-end of treatment
10. Proportion of participants achieving sustained suppression of HBV DNA ( $< \text{LLOQ}$ ) after discontinuation of all treatment:
  - 10.1. At 24 weeks
  - 10.2. At the F48 Follow-Up visit
11. Proportion of participants achieving sustained suppression of HBV DNA ( $< \text{LLOQ}$ ) with HBsAg loss ( $< 0.05$  IU/ml) after discontinuation of all treatment:
  - 11.1. At 24 weeks
  - 11.2. At the F48 Follow-Up visit
12. For HBeAg-positive participants: proportion of participants with HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion
13. Incidence and titers of anti-drug antibodies (ADA; if applicable) to VIR-3434
14. Mean change in serum HBsAg level from baseline across time points in the study
15. Proportion of participants achieving HBV DNA ( $< \text{LLOQ}$ ) across time points in the study
16. Proportion of participants achieving ALT  $\leq \text{ULN}$  across time points in the study

#### THRIVE:

9. Proportion of participants with HBsAg loss ( $< 0.05$  IU/mL) at 24 weeks post-end of treatment
  10. Proportion of participants achieving sustained suppression of HBV DNA ( $< \text{LLOQ}$ ) after discontinuation of all treatment:
    - 10.1. At 24 weeks
    - 10.2. At 48 weeks
  11. Proportion of participants achieving sustained suppression of HBV DNA ( $< \text{LLOQ}$ ) with HBsAg loss ( $< 0.05$  IU/mL) after discontinuation of all treatment:
    - 11.1. At 24 weeks
    - 11.2. At 48 weeks
  12. Incidence and titers of anti-drug antibodies (ADA; if applicable) to VIR-3434
  13. Mean change in serum HBsAg level from baseline across time points in the study
  14. Proportion of participants achieving HBV DNA ( $< \text{LLOQ}$ )
- All outcomes measured using drawn blood

#### Completion date

05/04/2023

#### Reason abandoned (if study stopped)

Participant recruitment issue

## Eligibility

**Key inclusion criteria**

1. Male or female aged 18 years old and over
2. Chronic HBV infection for  $\geq$  6 months
3. A Body Mass Index (BMI) less than 18 kg/m<sup>2</sup> or greater than 35 kg/m<sup>2</sup>

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

All

**Key exclusion criteria**

1. History or current suspicion of malignancy diagnosed or treated within 5 years
2. Any clinically significant medical or psychiatric condition that may interfere with study intervention, assessment, or compliance with the protocol or otherwise makes the participant unsuitable for participation in the study
3. History or evidence of drug or alcohol abuse
4. History of hepatic decompensation

**Date of first enrolment**

18/10/2022

**Date of final enrolment**

30/04/2025

**Locations****Countries of recruitment**

New Zealand

**Study participating centre**

**Auckland City Hospital**

2 Park Road, Grafton

Auckland

New Zealand

1010

**Study participating centre**

## **Middlemore Clinical Trials**

Esme, Green Building 100 Hospital Road, Middlemore Hospital  
Auckland  
New Zealand  
2025

## **Study participating centre**

### **P3 Research Ltd. (Tauranga)**

Suite 11, Promed House, 71 Tenth Avenue  
Tauranga  
New Zealand  
3110

## **Study participating centre**

### **Waikato Hospital**

183 Pembroke Street  
Hamilton  
New Zealand  
3204

# **Sponsor information**

## **Organisation**

VIR Biotechnology (United States)

## **ROR**

<https://ror.org/030pjfg04>

## **Organisation**

Novotech (New Zealand) Limited c/o Novotech (Australia) Pty Ltd

# **Funder(s)**

## **Funder type**

Industry

## **Funder Name**

Vir Biotechnology

**Alternative Name(s)**

Vir Biotechnology Inc, Vir Biotechnology, Inc., Vir

**Funding Body Type**

Government organisation

**Funding Body Subtype**

For-profit companies (industry)

**Location**

United States of America

## **Results and Publications**

**Individual participant data (IPD) sharing plan**

The data-sharing plans for the current study are unknown and will be made available at a later date

**IPD sharing plan summary**

Data sharing statement to be made available at a later date